Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$22.57 - $33.14 $248,270 - $364,540
11,000 Added 13.43%
92,900 $2.28 Million
Q2 2024

Aug 14, 2024

BUY
$21.22 - $32.66 $700,260 - $1.08 Million
33,000 Added 67.48%
81,900 $1.92 Million
Q1 2024

May 15, 2024

SELL
$23.46 - $45.07 $260,406 - $500,277
-11,100 Reduced 18.5%
48,900 $1.62 Million
Q4 2023

Feb 14, 2024

SELL
$17.69 - $30.76 $1.37 Million - $2.39 Million
-77,600 Reduced 56.4%
60,000 $1.63 Million
Q3 2023

Nov 14, 2023

BUY
$23.01 - $32.46 $2.54 Million - $3.58 Million
110,200 Added 402.19%
137,600 $3.31 Million
Q2 2023

Aug 14, 2023

SELL
$29.32 - $35.99 $1.16 Million - $1.42 Million
-39,400 Reduced 58.98%
27,400 $874,000
Q1 2023

May 15, 2023

BUY
$30.15 - $48.79 $198,990 - $322,014
6,600 Added 10.96%
66,800 $2.05 Million
Q4 2022

Feb 14, 2023

SELL
$36.73 - $51.6 $5.41 Million - $7.61 Million
-147,400 Reduced 71.0%
60,200 $2.35 Million
Q3 2022

Nov 14, 2022

BUY
$39.79 - $70.31 $5.28 Million - $9.34 Million
132,800 Added 177.54%
207,600 $9.89 Million

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.72B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.